NovoCure (NAS:NVCR) Price-to-Free-Cash-Flow

: 642.36 (As of Today)

View and export this data going back to 2015. Start your Free Trial

As of today (2023-03-25), NovoCure's share price is $57.17. NovoCure's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2022 was $0.09. Hence, NovoCure's Price-to-Free-Cash-Flow Ratio for today is 642.36.

The historical rank and industry rank for NovoCure's Price-to-Free-Cash-Flow or its related term are showing as below:

NVCR' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 97.6 Med: 298.06 Max: 1438.97
Current: 623.98

During the past 10 years, NovoCure's highest Price-to-Free-Cash-Flow Ratio was 1438.97. The lowest was 97.60. And the median was 298.06.

NVCR's Price-to-Free-Cash-Flow is ranked worse than
98.11% of 318 companies
in the Medical Devices & Instruments industry
Industry Median: 34.39 vs NVCR: 623.98

NovoCure's Free Cash Flow per Share for the three months ended in Dec. 2022 was $-0.10. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $0.09.

During the past 12 months, the average Free Cash Flow per Share Growth Rate of NovoCure was -84.10% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was -18.50% per year.

During the past 10 years, NovoCure's highest 3-Year average Free Cash Flow per Share Growth Rate was 70.50% per year. The lowest was -23.30% per year. And the median was 3.00% per year.

NovoCure Price-to-Free-Cash-Flow Historical Data

The historical data trend for NovoCure's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovoCure Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Price-to-Free-Cash-Flow

507.65

223.86

132.65

815.00

NovoCure Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Price-to-Free-Cash-Flow																132.65	238.07	300.87	406.31	815.00

Competitive Comparison

For the Medical Instruments & Supplies subindustry, NovoCure's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annual Data Quarterly Data

NovoCure Price-to-Free-Cash-Flow Distribution

For the Medical Devices & Instruments industry and Healthcare sector, NovoCure's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where NovoCure's Price-to-Free-Cash-Flow falls in comparison to its industry or sector. The grey bar indicates the Price-to-Free-Cash-Flow's extreme value range as defined by GuruFocus.

NovoCure Price-to-Free-Cash-Flow Calculation

NovoCure's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio	=	Share Price	/	Free Cash Flow per Share (TTM)
	=	57.17	/	0.089
	=	642.36

NovoCure's Share Price of today is $57.17.
NovoCure's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.09.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio

Market Cap

Free Cash Flow

NovoCure (NAS:NVCR) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.

Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.

NovoCure Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of NovoCure's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

NovoCure (NAS:NVCR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NovoCure Ltd (NAS:NVCR) » Definitions » Price-to-Free-Cash-Flow

Comparable Companies

Traded in Other Exchanges

NVCR:Mexico 038:Germany

Address

Grenville Street, No. 4 The Forum, Second Floor, St. Helier, JEY, JE2 4UF

Website

https://www.novocure.com

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves commercial-stage oncology operations involving therapies to cure critical tumors. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. NovoCure derives its major revenues in the United States.

Executives

Arye Barak Ben	officer: General Counsel	TOPAZ BUILDING, 4TH FLOOR, MATAM CENTER, PO BOX 15022, SH'AR HACARMEL, HAIFA L3 31905
William Patrick Burke	officer: Chief Human Resources Officer	195 COMMERCE WAY, PORTSMOUTH NH 03801
Timothy J Scannell	director	2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002
Ashley Cordova	officer: Chief Financial Officer	20 VALLEY STREAM PARKWAY,, SUITE 300, MALVERN PA 19355
Frank X Leonard	officer: Chief Development Officer	20 VALLEY STREAM PARKWAY,, SUITE 300, MALVERN PA 19355
Uri Weinberg	officer: Chief Science Officer	NOVOCURE INC., 20 VALLEY STREAM PARKWAY, SUITE 300, MALVERN PA 19355
Ely Benaim	officer: Chief Medical Officer	C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD, SUITE 455, ROCKVILLE MD 20850
Jeryl L Hilleman	director	C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Pritesh Shah	officer: Chief Commercial Officer	C/O NOVOCURE INC., 20 VALLEY STREAM PARKWAY, SUITE 300, MALVERN PA 19355
Sherilyn S Mccoy	director	JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
David Hung	director	C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Martin J. Madden	director	C/O MICROBOT MEDICAL INC., 175 DERBY STREET 27/1, HINGHAM MA 02043
Steve Futrell	10 percent owner	780 THIRD AVENUE, 46TH FLOOR, NEW YORK NY 10017
Frances Janis	10 percent owner	780 THIRD AVENUE, 46TH FLOOR, NEW YORK NY 10017
Michael D Granoff	10 percent owner	780 THIRD AVENUE, 46TH FLOOR, NEW YORK NY 10017